2019 International Congress

Wednesday, September 25, 2019

1:15pm-2:45pm

Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)

Epidemiology  ·  Les Muses, Level 3

1:15pm-2:45pm

Evaluating Perceptions of Deep Brain Stimulation in DBS-naïve Patients with Parkinson’s Disease – A Pilot Study

S. Das, S. Ramesh, M. Baldassari, M. Rasool, J. Ratliff, D. Kremens, T. Alexander, C. Matias, TW. Liang, C. Wu (Philadelphia, PA, USA)

Surgical Therapy  ·  Les Muses Terrace, Level 3

1:15pm-2:45pm

Evaluating Volume Changes in the Substantia Nigra Pars Compacta (SNc) in Parkinson’s Disease (PD) in a Study-Specific Magnetic Resonance Imaging (MRI) Template

E. Biondetti, R. Gaurav, L. Yahia-Cherif, G. Mangone, N. Pyatigorskaya, R. Valabregue, C. Ewenczyk, M. Hutchison, JC. Corvol, MJ. Vidailhet, S. Lehéricy (Paris, France)

Neuroimaging  ·  Les Muses Terrace, Level 3

1:15pm-2:45pm

Evaluation of Device-Assisted Treatment using a wearable accelerometry wrist sensor

A. Johansson, M. Lundgren, M. öthman, D. Nyholm (Stockholm, Sweden)

Phenomenology and Clinical Assessment of Movement Disorders  ·  Les Muses Terrace, Level 3

1:15pm-2:45pm

Evaluation of gut microbiota in patients with Parkinson’s disease using a gas chromatography–mass spectrometry in Russia

I. Krasakov, I. Litvinenko (Saint-Petersburg, Russian Federation)

Non-Motor Symptoms  ·  Agora 3 West, Level 3

1:15pm-2:45pm

Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, F. Niccolini, G. Dervenoulas, R. Tyacke, J. Myers, R. Gunn, D. Nutt, E. Rabiner, S. Tabrizi, M. Politis (London, United Kingdom)

Neuroimaging  ·  Les Muses Terrace, Level 3

1:15pm-2:45pm

Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study

H. Wilson, G. Dervenoulas, G. Pagano, R. Tyacke, J. Myers, R. Gunn, E. Rabiner, D. Nutt, M. Politis (London, United Kingdom)

Neuroimaging  ·  Les Muses Terrace, Level 3

1:15pm-2:45pm

Evaluation of nigral neuronal apoptosis during postnatal development and adulthood of mice strains with differential sensitivity to MPTP

Y. H, V. Dj, C. Sagar, R. Tr, P. Alladi (Bangalore, India)

Physiology and Pathophysiology  ·  Les Muses, Level 3

1:15pm-2:45pm

Evaluation of the Zeez Sleep Pebble for Sleep Disturbance in Parkinson’s Disease

S. Milne, S. Cummins, C. Carroll (Plymouth, United Kingdom)

Non-Motor Symptoms  ·  Agora 3 West, Level 3

1:15pm-2:45pm

Evidence of altered Serotonergic Network in Parkinson’s disease by using a multi-modal MRI and PET imaging approach

SP. Caminiti, Z. Chappell, A. Carotenuto, G. Dervenoulas, T. Yousaf, G. Pagano, H. Wilson, M. Politis (London, United Kingdom)

Neuroimaging  ·  Les Muses Terrace, Level 3